ACRV

Acrivon Therapeutics, Inc.

Pharmaceutical Preparations · SIC 2834CIK 1781174Held by 1 tracked managerEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

Revenue FY2025

—

Net Income FY2025

$(78.0M)

EPS (Basic, as reported)

$-2.02

Net Margin FY2025

—

ROE FY2025

-69.2%

Total Equity

$113.0M

Shares Out

43M

Business description

Acrivon Therapeutics, Inc. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2021–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions

default rows · click any row to chart itNet income: (16) → (78)

Fiscal yearFY2021⚑FY2022⚑FY2023⚑FY2024FY2025

Research & development—(24)(46)(64)(60)

General & administrative—(9)(21)(25)(24)

Total operating expenses(16)(33)(67)(89)(84)

Operating income(16)(33)(67)(89)(84)

Interest & investment income—27——

Other income (expense), net01796

Pre-tax income———(80)(78)

Income tax expense————0

Net income(16)(31)(60)(81)(78)

EPS — basic($9.32)($7.56)($2.74)($2.38)($2.02)

EPS — diluted($9.32)($7.56)($2.74)($2.38)($2.02)

Shares outstanding — basic (M)24223439

Shares outstanding — diluted (M)24223439

⚑ Weighted-average shares changed ×2.00 between FY2021 and FY2022 — likely a stock split. Per-share figures on either side are as reported and not adjusted.
⚑ Weighted-average shares changed ×5.50 between FY2022 and FY2023 — likely a stock split. Per-share figures on either side are as reported and not adjusted.
⚑ Weighted-average shares changed ×1.55 between FY2023 and FY2024 — likely a stock split. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.